Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Regulatory

New pharmaceutical legislation in Europe agreed

The agreement is the most significant overhaul of the regulatory framework in more than 20 years and represents a huge opportunity to reshape medicines regulation in the EU
Design & Build

Guardtech Group celebrates record 2025 with global cleanroom expansion

A landmark year sees mobile, modular and GMP cleanrooms delivered across healthcare, pharma and microelectronics
Pharmaceutical

Cytiva and Fida Biosystems unite to improve molecular insight for faster drug discovery

The collaboration will combine complementary and orthogonal approaches to simplify workflows and improve confidence in experimental results
Manufacturing

SeaBeLife partners with Unither Pharmaceuticals for ophthalmic drug production

The new partnership aims to produce clinical and commercial batches of ophthalmic formulation of SeaBeLife’s drug candidate SBL03 to treat degenerative disorders of the retina, such as dry age-related macular degeneration
Pharmaceutical

SGS achieves breakthrough in infectious disease research with launch of novel RSV A-strain

Derived from a 2015 circulating strain, SGS's novel RSV-A challenge agent offers a closer match to circulating RSV viruses than strains currently used in clinical research
Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Pharmaceutical

Samsung Bioepis expands European biosimilar portfolio with OBODENCE and XBRYK launches

The products, targeting osteoporosis and bone-related complications in cancer, strengthen access to affordable care and expand the company’s direct sales footprint across endocrinology and oncology
Subscribe now